# US 2008/0292733 A1 · Antioxidant and Fe2+ Chelating Properties of Herbal Extracts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0292733 A1
- Document ID: US20080292733A1
- Status: Published application
- Kind: A1
- Application number: 12/090,957
- Filed: 2006-10-16
- Published: 2008-11-27
- Earliest claimed: 2005-10-21
- Inventors: Sharla K. Sutherland; Jacqueline J. Shan
- Web page: https://patentgrep.com/patent/US20080292733A1

## CPC

- A61K 31/365: Lactones
- A61K 36/16: Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
- A61K 36/258: Panax (ginseng)
- A61K 36/38: Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/06: for tuberculosis
- A61P 35/00: Antineoplastic agents
- A61P 39/04: Chelating agents
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to antioxidative and antiproliferative agents containing North American ginseng (proprietary extract HT1001) alone or in combination with Ginkgo biloba (GB), Saint John's Wort (SJW), ginkgolides, flavonoids, ginsenosides, hypericin, and/or hyperforin. The antioxidative and antiproliferative agents according to the present invention show significant inhibition of Fe2+-catalyzed lipid peroxidation and Fe2+ chelation activity, the ability to scavenge hydroxyl free radicals, the ability to reduce neuroblastoma cell numbers, and/or the ability to promote neurite outgrowth. These effects are consistent with the behavior of Fe2+ chelators and the variance in both type and magnitude of effects exerted by the chemical components suggests a synergistic mechanism of action.

## Claims

### Claim at position 1

1-4. (canceled)

### Claim 5

A method for treating oxidative stress, comprising administering, in an amount effective to reduce oxidative stress, a pharmaceutical composition comprising HT1001, an American ginseng extract that has a total ginsenoside content which is about 25-50% by weight, in combination with at least one agent selected from the group consisting of Ginkgo biloba, Saint John's Wort, ginkgolides, flavonoids, ginsenosides, hypericin, and hyperforin, to a patient in need of such treatment.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said oxidative stress is due to cancer, Alzheimer's disease, tuberculosis, Parkinson's disease, sickle cell, Wilson, liver damage, beta-thalassemia, heart disease, multiple sclerosis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), infection, neoplasia, cardiomyopathy, or arthropathy.

### Claim 7

A method for treating iron overload comprising administering, in an amount effective to reduce iron overload, a pharmaceutical composition comprising HT1001, an American ginseng extract that has a total ginsenoside content which is about 25-50% by weight, in combination with at least one agent selected from the group consisting of Ginkgo biloba, Saint John's Wort, ginkgolides, flavonoids, ginsenosides, hypericin, and hyperforin, to a patient in need of such treatment.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said iron overload is due to cancer, Alzheimer's disease, tuberculosis, Parkinson's disease, sickle cell, Wilson, liver damage, beta-thalassemia, heart disease, multiple sclerosis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), infection, neoplasia, cardiomyopathy, or arthropathy.

### Claim 9

A method for promoting neurite outgrowth comprising administering, in an amount effective to promote neurite outgrowth, a pharmaceutical composition comprising HT1001, an American ginseng extract that has a total ginsenoside content which is about 25-50% by weight, in combination with at least one agent selected from the group consisting of Ginkgo biloba, ginkgolides, flavonoids, and ginsenosides, to a patient in need of such treatment.

### Claim 10 (depends on 9)

The method according to claim 9, wherein promoting neurite outgrowth is needed to treat Alzheimer's disease, Parkinson's disease, infection, and neuroblastoma.
